Tests and Procedures

Our Clinical Laboratory Services cover diversified diagnoses that patients and physicians need in making healthcare decisions such as

Find a test or procedure by its first letter

Find a test or procedure by its first letter

Find a test or procedure by its first letter

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

MM980 : ACTImmune (ACT Genomics)

Comment

Test Code
MM980
Test Name
ACTImmune (ACT Genomics)
Department
Bio - Molecular Laboratory
Sample Type/Volume
Please provide one of the tumor tissue type (1 of 5) AND WITH whole blood 8 ml blood in Strek tube (Deliver within 4 days) FFPE: 1. Surgical => 5 unstain slides + 1 H&E slide 2. Core Needle Biopsies => 6 unstain slides + 1 H&E slide 3. DNA > 200 ng 4. Pleural Effusion => Cell block + 1 H&E slide 5. Ascites => Cell block + 1 H&E slide
Storage Condition
Room temperature
Collection Remark
-
Principle
NGS-based whole exon sequencing (>18,000 genes) HLA classI Microsatellite instability
Method
NGS-based whole exon sequencing (>18,000 genes) HLA classI Microsatellite instability
Reference Range
-
Clinical
       Immune system plays a critical role in controlling and fighting cancer. In recent studies, several antibody therapies capable of restoring or enhancing the immune response have demonstrated significant success for patients with a variety of malignancies. Blockade of the negative immuno-logic regulators, CTLA-4 and PD-1, can result in anti-tumor immunity and revolutionized cancer treatment. Because of the successes with immune checkpoint inhibitors in cancer immunotherapy, many combinational approaches and new agents are being developed.
     However, the efficacy of immune checkpoint inhibitors vary among different tumor types and genomics alternations in cancer cells, only 20%to 30% of patients are likely to benefit from the treatment. Therefore, it is critical to have an accurate way to predict the response to the drugs. Recent studies have revealed the high nonsynonymous mutation burden in tumor and the number of neo-antigens to be presented by MHC are associated with response to the therapy.
Turnaround Time
45 Days
Operation Schedule
N/A